Vaccines are considered to be one of the greatest public health achievements of the last century, so when the COVID-19 pandemic brought the world to a stop, all energies were focused on bringing a vaccine to market.
With multiple vaccines now approved and being manufactured in record time, we celebrate this accelerated pace of development in the field. Exploring the different vaccine technologies to understand their mode of action, benefits, risks, and potential real-life impact on protection. The challenges in manufacturing enough doses to vaccinate the world and the potential impact the WTO’s IP waiver proposal will have on future innovation.
- Vaccine Science: Two Centuries of Continuous Research, Improvements, and Achievements
- Future Potential of mRNA
- Where are the facilities equipped for these new molecule types? What problems are arising and how is the industry working to fix them?
- Vaccinating the world, a look at WTO’s proposed IP waiver and what it could mean for future innovation
This session was originally broadcast live as part of CPhI North America 2021.
- Leonard Friedland, Vice President, Director Scientific Affairs and Public Health, GSK Vaccines
- Fiona Barry, Associate Editor, Global Data
- Dr Fintan Walton, CEO of PharmaVentures
In this special edition of PharmaVentures Insights, Dr Fintan Walton, Founder & CEO, leads a panel discussion to address whether a duel strategy of approaching both a pharmaceutical company for partnering, and a VC for funding at the same time, is the best way forward for an emerging biotech.
Panelists include Tomas Landh, Innovation Sourcing VP, Senior Principal Scientist Search and Evaluation at Novo Nordisk, Jeanne Bolger, Vice President, Venture Investments at J&J Innovation, Bart Dzikowski, Managing Director, Head of Transactions & Legal at Novartis Venture Fund, Tim Luker, Senior Director, External Innovation, Global External R&D at Eli Lilly and Kevin Johnson, Co-Founder at Medicxi.
In this exclusive interview, Fintan Walton, CEO of PharmaVentures, speaks with Marc Funk, the new CEO of Recipharm.
Recipharm is a leading Swedish CDMO, founded in 1995, which has expanded to over 30 sites across 10 countries which are mainly in Europe, but also in Israel, India, and North America. The company’s successful inorganic growth has been largely through the build and buy model of its founders, according to Marc.
They discuss the company’s current situation and how Marc plans to take it forward, including:
- The takeover of Recipharm by EQT, a global investment organisation with a “passion for future-proofing companies”
- Focus on operational excellence, meeting the needs unmet by the competition, emerging technologies, and innovation
- Opportunities in the areas of small molecules, biologics, and North America
- Recipharm’s and EQT’s “priority 1” – customer focus
- Affordable and safe drugs
- How Recipharm are operating during the COVID-19 pandemic
- What Marc sees as his biggest challenges, both now and in the future